Overview
Myriad Genetics, Inc., based in the United States, operates prominently within the biotechnology industry, focusing primarily on molecular diagnostics and personalized medicine. Established with the aspiration to advance patient care through genetic insights, Myriad Genetics specializes in developing and marketing predictive, personalized, and prognostic tests across various medical disciplines. Its key projects include pioneering work in hereditary cancer screening, particularly with the BRCA gene tests, and expansions into tests for depression medication response (GeneSight) and rheumatoid arthritis. The company emphasizes innovation in genetic research to facilitate early disease detection and optimized treatment, reflecting its commitment to enhancing patient health outcomes through cutting-edge genetic screening technologies.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Myriad Genetics, Inc. as of June 30, 2025 is 832.90 MM.
- The operating income for Myriad Genetics, Inc. as of June 30, 2025 is -76.70 MM.
- The net income for Myriad Genetics, Inc. as of June 30, 2025 is -395.20 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 832.90 | -76.70 | -395.20 |
| 2025-03-31 | 831.30 | -89.10 | -101.40 |
| 2024-12-31 | 837.60 | -88.00 | -127.30 |
| 2024-09-30 | 823.60 | -95.40 | -116.00 |
| 2024-06-30 | 802.20 | -103.30 | -155.20 |
| 2024-03-31 | 774.20 | -120.30 | -234.60 |
| 2023-12-31 | 753.20 | -138.90 | -263.30 |
| 2023-09-30 | 734.40 | -172.20 | -274.40 |
| 2023-06-30 | 698.90 | -191.40 | -248.20 |
| 2023-03-31 | 694.70 | -155.90 | -146.20 |
| 2022-12-31 | 678.40 | -123.70 | -112.00 |
| 2022-09-30 | 661.40 | -58.80 | -77.30 |
| 2022-06-30 | 672.30 | -93.70 | -17.60 |
| 2022-03-31 | 682.40 | -106.30 | -8.20 |
| 2021-12-31 | 690.60 | -126.70 | -27.20 |
| 2021-09-30 | 684.40 | -192.70 | -57.50 |
| 2021-06-30 | 662.30 | -153.50 | -97.30 |
| 2021-03-31 | 566.10 | -202.80 | -148.00 |
| 2020-12-31 | 557.00 | -194.80 | -223.70 |
| 2020-09-30 | 597.50 | -155.30 | -194.10 |
Income Statement: EPS
- The earnings per share basic for Myriad Genetics, Inc. as of June 30, 2025 is -4.32.
- The earnings per share diluted for Myriad Genetics, Inc. as of June 30, 2025 is -4.33.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -4.32 | -4.33 |
| 2025-03-31 | -1.11 | -1.12 |
| 2024-12-31 | -1.41 | -1.41 |
| 2024-09-30 | -1.30 | -1.30 |
| 2024-06-30 | -1.78 | -1.78 |
| 2024-03-31 | -2.76 | -2.77 |
| 2023-12-31 | -3.18 | -3.18 |
| 2023-09-30 | -3.37 | -3.36 |
| 2023-06-30 | -3.06 | -3.06 |
| 2023-03-31 | -1.81 | -1.80 |
| 2022-12-31 | -1.39 | -1.39 |
| 2022-09-30 | -0.96 | -0.97 |
| 2022-06-30 | -0.22 | -0.22 |
| 2022-03-31 | -0.10 | -0.11 |
| 2021-12-31 | -0.35 | -0.35 |
| 2021-09-30 | -0.75 | -0.75 |
| 2021-06-30 | -1.28 | -1.29 |
| 2021-03-31 | -1.97 | -1.97 |
| 2020-12-31 | -2.99 | -2.99 |
| 2020-09-30 | -2.60 | -2.60 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Myriad Genetics, Inc. as of June 30, 2025 is -22.60 MM.
- The cash from investing activities for Myriad Genetics, Inc. as of June 30, 2025 is -13.60 MM.
- The cash from financing activities for Myriad Genetics, Inc. as of June 30, 2025 is 15.20 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -22.60 | -13.60 | 15.20 |
| 2025-03-31 | -6.40 | -13.10 | 15.00 |
| 2024-12-31 | -8.70 | -11.90 | -7.40 |
| 2024-09-30 | -70.00 | -18.00 | 112.40 |
| 2024-06-30 | -92.80 | -28.00 | 113.00 |
| 2024-03-31 | -96.30 | -9.80 | 149.00 |
| 2023-12-31 | -110.90 | 31.90 | 152.90 |
| 2023-09-30 | -63.50 | 8.30 | 28.90 |
| 2023-06-30 | -44.20 | 22.20 | 27.80 |
| 2023-03-31 | -93.00 | -1.60 | -8.10 |
| 2022-12-31 | -106.30 | -77.50 | -8.00 |
| 2022-09-30 | -108.50 | -67.80 | -7.00 |
| 2022-06-30 | -145.00 | 211.80 | -77.90 |
| 2022-03-31 | -99.70 | 224.90 | -106.90 |
| 2021-12-31 | 18.60 | 274.40 | -150.60 |
| 2021-09-30 | 13.70 | 311.30 | -147.70 |
| 2021-06-30 | -6.30 | 37.30 | -77.10 |
| 2021-03-31 | 28.10 | 46.60 | -49.70 |
| 2020-12-31 | -26.90 | 61.60 | -1.00 |
| 2020-09-30 | -14.40 | 43.50 | -1.60 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Myriad Genetics, Inc. as of June 30, 2025 is -4.83.
- The p/book for Myriad Genetics, Inc. as of June 30, 2025 is 0.69.
- The p/tbv for Myriad Genetics, Inc. as of June 30, 2025 is 3.04.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | -4.83 | 0.69 | 3.04 |
| 2025-03-31 | 1.16 | 5.32 | |
| 2024-12-31 | 1.70 | 9.34 | |
| 2024-09-30 | -15.48 | 3.25 | 17.84 |
| 2024-06-30 | -9.43 | 2.91 | 16.75 |
| 2024-03-31 | 2.44 | 13.08 | |
| 2023-12-31 | -6.18 | 2.48 | 42.19 |
| 2023-09-30 | -5.29 | 1.79 | 14.72 |
| 2023-06-30 | -12.82 | 2.24 | 10.49 |
| 2023-03-31 | -16.83 | 2.13 | |
| 2022-12-31 | 1.28 | 3.80 | |
| 2022-09-30 | 1.63 | 4.71 | |
| 2022-06-30 | 1.54 | 4.59 | |
| 2022-03-31 | -74.14 | 2.08 | 6.21 |
| 2021-12-31 | 36.75 | 2.28 | 7.02 |
| 2021-09-30 | 124.85 | 2.79 | 10.71 |
| 2021-06-30 | |||
| 2021-03-31 | -54.92 | 1.91 | -128.86 |
| 2020-12-31 | -7.36 | 1.87 | -66.67 |
| 2020-09-30 | -8.46 | 1.81 | -165.90 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Myriad Genetics, Inc. as of June 30, 2025 is -0.28.
- The ebit (3y)/ev for Myriad Genetics, Inc. as of June 30, 2025 is -0.40.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.28 | -0.40 |
| 2025-03-31 | -0.17 | -0.23 |
| 2024-12-31 | -0.10 | -0.15 |
| 2024-09-30 | -0.07 | -0.08 |
| 2024-06-30 | -0.11 | -0.07 |
| 2024-03-31 | -0.14 | -0.08 |
| 2023-12-31 | -0.17 | -0.08 |
| 2023-09-30 | -0.21 | -0.10 |
| 2023-06-30 | -0.09 | -0.05 |
| 2023-03-31 | -0.08 | -0.07 |
| 2022-12-31 | -0.12 | -0.11 |
| 2022-09-30 | -0.03 | -0.06 |
| 2022-06-30 | -0.03 | -0.08 |
| 2022-03-31 | -0.03 | -0.06 |
| 2021-12-31 | 0.02 | -0.03 |
| 2021-09-30 | -0.02 | -0.04 |
| 2021-06-30 | ||
| 2021-03-31 | -0.06 | -0.05 |
| 2020-12-31 | -0.16 | -0.05 |
| 2020-09-30 | -0.14 | -0.04 |
Management Effectiveness
- The roa for Myriad Genetics, Inc. as of June 30, 2025 is -0.09.
- The roe for Myriad Genetics, Inc. as of June 30, 2025 is -0.14.
- The roic for Myriad Genetics, Inc. as of June 30, 2025 is -0.12.
- The croic for Myriad Genetics, Inc. as of June 30, 2025 is -0.01.
- The ocroic for Myriad Genetics, Inc. as of June 30, 2025 is -0.01.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.09 | -0.14 | -0.12 | -0.01 | -0.01 |
| 2025-03-31 | -0.11 | -0.17 | -0.15 | -0.03 | -0.01 |
| 2024-12-31 | -0.10 | -0.15 | -0.13 | 0.03 | -0.08 |
| 2024-09-30 | -0.14 | -0.23 | -0.18 | -0.01 | -0.11 |
| 2024-06-30 | -0.20 | -0.28 | -0.26 | 0.05 | -0.11 |
| 2024-03-31 | -0.22 | -0.30 | -0.28 | 0.08 | -0.12 |
| 2023-12-31 | -0.23 | -0.30 | -0.31 | -0.03 | -0.07 |
| 2023-09-30 | -0.21 | -0.26 | -0.26 | 0.01 | -0.05 |
| 2023-06-30 | -0.12 | -0.15 | -0.28 | 0.01 | -0.05 |
| 2023-03-31 | -0.09 | -0.12 | -0.15 | -0.10 | -0.09 |
| 2022-12-31 | -0.06 | -0.08 | -0.07 | -0.18 | -0.10 |
| 2022-09-30 | -0.01 | -0.02 | -0.07 | -0.18 | -0.10 |
| 2022-06-30 | -0.01 | -0.01 | -0.02 | -0.01 | -0.14 |
| 2022-03-31 | -0.02 | -0.03 | -0.01 | 0.02 | -0.10 |
| 2021-12-31 | 0.04 | 0.07 | -0.02 | 0.12 | -0.09 |
| 2021-09-30 | 0.01 | 0.02 | 0.05 | 0.04 | -0.11 |
| 2021-06-30 | 0.01 | 0.02 | 0.02 | -0.14 | -0.10 |
| 2021-03-31 | -0.02 | -0.03 | -0.14 | 0.03 | -0.08 |
| 2020-12-31 | -0.14 | -0.21 | -0.19 | 0.03 | -0.13 |
| 2020-09-30 | -0.12 | -0.18 | -0.16 | 0.02 | -0.01 |
Gross Margins
- The gross margin for Myriad Genetics, Inc. as of June 30, 2025 is 0.70.
- The net margin for Myriad Genetics, Inc. as of June 30, 2025 is -0.12.
- The operating margin for Myriad Genetics, Inc. as of June 30, 2025 is -0.11.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.70 | -0.12 | -0.11 |
| 2025-03-31 | 0.70 | -0.15 | -0.10 |
| 2024-12-31 | 0.69 | -0.14 | -0.12 |
| 2024-09-30 | 0.69 | -0.19 | -0.13 |
| 2024-06-30 | 0.69 | -0.30 | -0.15 |
| 2024-03-31 | 0.69 | -0.35 | -0.19 |
| 2023-12-31 | 0.69 | -0.37 | -0.22 |
| 2023-09-30 | 0.68 | -0.36 | -0.26 |
| 2023-06-30 | 0.69 | -0.36 | -0.26 |
| 2023-03-31 | 0.70 | -0.21 | -0.23 |
| 2022-12-31 | 0.70 | -0.12 | -0.09 |
| 2022-09-30 | 0.71 | -0.12 | -0.09 |
| 2022-06-30 | 0.71 | -0.03 | -0.14 |
| 2022-03-31 | 0.72 | -0.01 | -0.14 |
| 2021-12-31 | 0.72 | -0.04 | -0.18 |
| 2021-09-30 | 0.72 | 0.08 | -0.22 |
| 2021-06-30 | 0.72 | 0.03 | -0.18 |
| 2021-03-31 | 0.70 | -0.26 | -0.36 |
| 2020-12-31 | 0.70 | -0.40 | -0.34 |
| 2020-09-30 | 0.70 | -0.32 | -0.27 |
Identifiers and Descriptors
| Central Index Key (CIK) | 899923 |
Industry Groups
| SIC 2835 - In Vitro and In Vivo Diagnostic Substances |
